HIV/AIDS HAART
High blood lipids observed with PIs increase 10-year coronary risk
Published in Obesity and Diabetes Week, May 2nd, 2005
"We investigated the effect of dyslipidemia associated with highly active antiretroviral therapy on cardiovascular risk and life expectancy among patients who had the human immunodeficiency virus.
"Dyslipidemia estimates were based on results from a phase 2 randomized trial that compared lipid changes after 32 weeks of therapy with atazanavir with those with nelfinavir (each in combination with stavudine and lamivudine)," wrote researchers in Canada.
"The resultant increased coronary risk was estimated using Framingham risk...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
Munc18c heterozygous knockout mice susceptible to glucose intolerance - Diabetes Therapy
Pioglitazone benefits patients with diabetes and metabolic syndrome - Diet and Nutrition
Caloric restriction effects on insulin-signaling system examined - Obesity Pathogenesis
Apolipoprotein C3 deficiency results in diet-induced obesity - Obesity and Diabetes
Activation of rapamycin pathway target involved in insulin resistance - Abdominal Obesity
GH treatment reduces abdominal visceral fat in postmenopausal women - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
